icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
05cj8GQcGvQYvs16
Listen
